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To complement the work reported by Konantz et al., 3 we analysed gene expression data generated from nucleated cells obtained from diagnostic bone marrow aspirates of 70 de novo ALL (31 female subjects, median age at diagnosis: 4.4 years, range: 1.1-14.6 years), using the Affymetrix U133 þ 2 platform from our previously published and verified data set. 7, 8 We analysed nine T-cell ALL, three BCR-ABL-rearranged Philadelphia-positive, one MLL-rearranged and 57 ALL with other cytogenetics, of which most were hyperdiploid. We focussed on EVI1 transcripts targeted by probes 226420_at and 221884_at, which detect exonic sequences of EVI1 transcripts. 5 We also included two large and sufficiently annotated gene expression data sets in our analysis, together comprising 455 de novo ALL samples (GEO Data sets GES28497 9 and GES13425 10 ). To determine whether high EVI1 expression in ALL is also associated with specific chromosomal changes involving BCR/ABL or MLL rearrangements, or T-cell phenotype, we divided de novo childhood ALL into four subgroups. We analysed T-cell ALL separately from BCR-ABL fusion (Philadelphia)-positive, MLL gene rearrangement-positive and ALL with other cytogenetic abnormalities (the largest group). In addition, and separately, we also analysed paired data sets of de novo and subsequently relapsed childhood ALL (GSE28460).
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EVI1 expression is variable in de novo paediatric ALL. However, the range of EVI1 expression levels is much smaller as compared with childhood AML (Figure 1a) . When applying the criteria used for paediatric AML with samples considered EVI1-positive ( þ ) when EVI1 expression is higher than log0.5 normalised fold change, the proportion of EVI1 þ ALLs is larger than AML and includes cases of T-cell ALL. There was no clear association of higher EVI1 expression levels with BCR-ABL or MLL rearrangements in the analysis of our own samples and results of published data sets (Figure 1a) . The variability of EVI1 expression in the MLLrearranged ALL group might be partly dependent on specific MLL gene rearrangements, as AMLs with MLL/AF6 and MLL/AF9 fusions are associated in particular with high EVI1 expression in adults and children. 5, 12 We found no obvious possible cause for variability of EVI1 expression in ALL of other cytogenetic subgroups. Given the rarity of 3q rearrangements in ALL, high EVI1 expression is likely to be a secondary event. Cytogenetic features of high EVI1-expressing ALL, which include hyperdiploid and normal karyotype disease, are listed in Supplementary Table 1 .
Konatz et al. 3 observed that EVI1 modulated the expression of apoptosis-related genes in paediatric ALL. In accordance with their data, 3 we identified BCLX (fold change À 1.8, P ¼ 0.007) and PUMA (FC ¼ À 1.9, P ¼ 0.005) in T-cell ALL when determining EVI1-coregulated genes by selecting for significantly changed (Po0.01, analysis of variance) low and high expressed genes in paediatric T-and B-cell ALL with EVI1 expression 4log1.5. To determine the overlap in global expression patterns associated with high EVI1 transcripts, we chose a 4log1.5 cutoff to analyse a meaningful sample size for comparison. In general, the overlap was greater between T-cell ALL and B-cell ALL than either of these groups with AML ( Supplementary Information, Figure 1 ). Only 12 genes were significantly co-regulated in all the subgroups of childhood leukaemia (Po0.01, analysis of variance) ( Supplementary  Information, Figure 1 ), with seven regulated in different directions between the subgroups. This included SMARCA5, of which the encoded protein recently has been shown to directly interact with the EVI1 protein in SKOV ovarian cancer cells and K562 leukaemia cells. 13 Importantly, we noted that several of the high EVI1-expressing ALLs were from patients in late childhood or adolescence. To further explore a possible association of EVI1 expression with age in de novo childhood ALL, we carried out rank regression analysis by age on our B-cell ALL cases, which is the largest group of our age-and sex-annotated data set (n ¼ 51), excluding those with MLL or BCR-ABL rearrangements. We found a highly significant increase in EVI1 expression with age at diagnosis of ALL (Figure 1bi , upper panel) during childhood years (age 1-10, r ¼ 0.29, P ¼ 0.05) but in particular obvious with the onset of adolescence (age 1-14, r ¼ 0.53, Po0.003). To further explore the relationship of patient age on gene expression patterns in childhood ALL we applied this approach to the entire data set. We identified 415 probe sets corresponding to 341 genes with significant ageassociated changes in expression levels (P ¼ 0.01) (Figure 1bii , lower panel). Of these, 130 genes have the highest expression in adolescence (cluster 3). When we associated the upstream regulators of these 130 genes (Ingenuity pathway analysis), we found that 21 are regulated directly by transforming growth factor-b (P ¼ 1.8 Â 10 contribute to age-dependent changes in ALL gene expression observed in the adolescent age group. As EVI1 also has been shown to have an impact on transforming growth factor-b signalling, 15 we have started to investigate this in more detail. When we analysed the age association of gene expression patterns in our AML data set (also excluding MLL-rearranged cases), we detected some striking differences to ALL. Although age has an impact on gene expression patterns also distinctly in AML, we see a negative correlation of EVI1 with increasing age (Supplementary Figure 2) .
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The data set by Hogan et al. 11 shows that in de novo ALL that subsequently relapses EVI1 expression has a significantly wider range compared with the de novo ALL cases that are not selected for subsequent relapse in the other studies (Po0.01). Importantly, paired analysis suggests that at ALL relapse, expression of EVI1 is on average higher than in the corresponding de novo sample (1.3-fold increased, Po0.006, Figure 1c) .
In summary, our analysis confirms high EVI1 expression in a group of paediatric ALL, which does not appear to be confined to distinct cytogenetic subtypes. The limited overlap of gene expression profiles associated with high EVI1 expression in different forms of childhood leukaemia and the different levels of expression of some co-regulated genes implies the possibility of tissue specificity, and the impact of cell of origin for EVI1-mediated transcriptional regulation, which has also been suggested for MLL-rearranged AML subtypes. 16 High EVI1 expression itself is likely to be a secondary event in paediatric lymphoblastic and myeloid leukaemia. The higher expression in older children might be linked to the worse prognosis of ALL in this age group. Whereas higher EVI1 expression in relapsed disease might be a function of increasing age, it also implies potentially a more general role in ALL stem cell survival. It will be important to prospectively investigate EVI1 in paediatric ALL for prognosis on current treatment regimens, and potential therapeutic benefit. In addition, our analysis strongly suggests an impact of age at diagnosis on gene expression patterns in childhood leukaemia. As we are uncertain to what extent this reflects the chronological age of the patient, or that of the cell of origin in childhood leukaemia, we have started to investigate this more comprehensively. 11 ). Expression of EVI1 was measured using the 221884_at Affymetrix gene probe set. Affymetrix gene expression microarray data normalisation was confirmed using multidimensional scaling in Qlucore Omics Explorer 2.3 and analysis of gene expression change was undertaken using a paired t-test with gender as an eliminated factor; q ¼ false discovery rate-modified P-value, FC ¼ fold change.
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